RESULTS: In 825,707 men, utilization of radiation therapy declined and utilization of radical prostatectomy increased for all prostate cancer risk-groups between 2004-2013 (p<0.0001). Observation for low-risk prostate cancer increased from 16.3% in 2004-2005 to 32.0% in 2012-2013 (p<0.0001). Significant treatment variation was observed based on Commission on Cancer-facility type. For all riskgroups, rates of treatment according to facility type ranged from 28.4% to 76.9% for radical prostatectomy, 3.6% to 16.2% for brachytherapy, 13.7% to 28.1% for external beam radiation therapy, 1.3% to 7.3% for androgen deprivation therapy, 4.6% to 19.1% for observation, and 0% to 2.1% for cryotherapy. The highest rates of observation for low-risk disease were observed in academic centers. After adjusting for sociodemographic and facility factors, the highest proportions of treatment variation attributable to the single institution were observed for CT (59%, 95%CI 0.45-0.73) and BT (46%, 95%CI 38-53%), while the lowest proportion of treatment variation was observed for ADT (14%, 95%CI 12-15%), and Observation (15%, 95%CI 14-17%). The results were consistent in the sensitivity analysis and in all NCCN risk-groups.
INTRODUCTION AND OBJECTIVES: Chemoprevention of prostate cancer (PCa) has been extensively investigated in the last decades. So far only 5-alpha-reductase-inhibitors (5-ARI) are supported by clinical evidence to have chemopreventive effect on PCa incidence, hence unclear in terms of prevention of aggressive PCa. Evidence for an effect of statins on PCa is conflicting. The interaction between dyslipidemia and carcinogenesis is still to be established. The aim of the study was to analyse the influence of statins intake on PSA values and PCa development.
METHODS: A population-based analysis including 4314 men from the European Randomized Study of Screening for Prostate Cancer (ERSPC) database was conducted. Data about drug intake, age, family history and symptoms was obtained by a self-administered questionnaire. A transrectal ultrasound guided prostate biopsy was performed in men with a PSA-level > 3ng/ml. Tumor stage and grade were registered, incidence and mortality data were obtained through registry linkages. PCa incidence and grade, total PSA value, free-to-total PSA and overall survival were compared between statin users and non-users, respectively. RESULTS: Over a follow-up period of 9.6 years men with statin (n¼761) exposure had insignificantly lower risk to be diagnosed with PCa ([stat+] hazard ratio (HR) 0.77, 95 % confidence interval (CI) 0.58 to 1.02. Statin users had less low risk PCa compared to non-users (p<0.05) at baseline visit while there was no difference in other PCa risk groups (according to d'Amico risk groups classification) or at follow-up visit. Interestingly, total PSA values were lower in statin users both for baseline (1.5 vs. 1.8 ng/ml, p<0.001) and follow-up-visits (after four years) (1.8 vs. 2.1ng/ml, p<0.001). Overall mortality was higher among statin users compared to non-users ([stat+] HR 1.67, 95% CI 1.36 to 2.04, however the competing risk analysis could demonstrate that PCa incidence was not influenced by overall-mortality.
CONCLUSIONS: In our study population we could demonstrate that statins intake did not alter overall PCa risk in a statistically significant manner. However, the finding of persistently lower PSA values in statin users is of potential clinical importance. It suggests that PSA cutoff values should be lowered in statin users otherwise it may introduce potential bias towards delayed PCa detection in this group, especially outside screening setting. On the other hand lower PSA values may suggest a durable protective effect of statins on PCa development.
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David Guo*, I-Chung Thomas, Harsha Mittakanti, Stanford, CA; Jeremy Shelton, Los Angeles, CA; Danil Makarov, New York, NY; Ted Skolarus, Ann Arbor, MI; Matthew Cooperberg, San Francisco, CA; Geoffrey Sonn, Benjamin Chung, James Brooks, John Leppert, Stanford, CA INTRODUCTION AND OBJECTIVES: Errors in prostate specific antigen (PSA) values included in prostate cancer registries have called into question clinical research studies that rely on this information. We sought to characterize the potential effects of PSA registry errors on clinical research by comparing cohorts based on registry PSA values with those based on laboratory values extracted from an integrated national health care system. METHODS: We defined three example cohorts of men with prostate cancer using data from the VA integrated health care system: those with 00 very low 00 (<4.0 ng/mL), 00 low 00 (<10.0 ng/mL), and 00 high 00 (20-100 ng/mL) PSA values. We compared the composition of each cohort when using the cancer registry versus the electronic health record PSA values. We compared overall survival for each cohort as an example clinical outcome. We fit multivariable proportional hazards models to determine the importance of the PSA source in each cohort.
RESULTS: There was significant discordance when using cancer registry versus electronic health record PSA values to identify a cohort of patients with 00 very low PSA 00 values. While 7,286 were included in both cohorts, one third (n¼3,515) of the cohort defined using cancer registry PSA values was misclassified and 1,800 additional patients were identified when using electronic health record data. The concordance was highest for patients with 00 low 00 PSA values, with 21,860 (98%) of patients identified in both the cancer registry and electronic health record based cohorts. Cancer registry PSA values misclassified 41% (604) of the 00 high 00 PSA cohort, and 133 additional patients were identified using electronic health record data. Comparisons of overall survival in the examples cohorts identified a difference in overall survival in the 00 very low 00 (log rank P¼0.03), but not the 00 low 00 or 00 high 00 PSA cohorts.
CONCLUSIONS: Patient cohorts based on cancer registry PSA values may have high rate of misclassification, particularly among patients with 00 very low 00 or 00 high 00 PSA values. In some cases, differences in cohorts resulted in measurable differences in overall survival. Attempts should be made to validate cancer registry PSA data to ensure accurate and reproducible results. INTRODUCTION AND OBJECTIVES: Prostate cancer progresses slowly, but its therapies often have adverse effects. Informed patient counselling regarding clinical outcomes is therefore important. The objective of this study was to identify all external validations of tools that predict clinical outcomes in prostate cancer patients undergoing radical prostatectomy, and evaluate which are optimum for clinical implementation.
METHODS: PubMed and Embase were systematically searched from 2007 to 2016. Search terms related to the inclusion criteria: prostate cancer, clinical outcomes, radical prostatectomy and prognosis. Titles/abstracts were screened and relevant studies were advanced to full-text review. The references of full-texts were reviewed for further studies. The Centre for Evidence-Based Medicine prognostic study tool was used for critical appraisal and the online tool Covidence was used for data extraction. RESULTS: Seventy-three studies externally validated 41 postand 13 pre-operative tools for the prediction of biochemical recurrence (BCR), aggressive BCR, metastasis, and prostate cancer specific mortality (PCSM). Recommendations for clinical implementation were made based on accuracy, cohort sizes, number of validations, and consistency. The accuracy of recommended tools ranged from 72-92% and 68-79% amongst the largest validation cohorts for post-and preoperative tools, respectively. For post-operative prognosis we recommend the CAPRA-S, Stephenson, Kattan, DPC and the Suardi nomograms for the prediction of BCR, the DPC nomogram for aggressive BCR, the CAPRA-S and Eggener nomograms for metastasis, and the Eggener nomogram for PCSM. For pre-operative prognosis we recommend the CAPRA and Stephenson nomograms for BCR, the D 0 Amico criteria for aggressive BCR, the CAPRA nomogram for metastasis, and the D 0 Amico criteria for PCSM.
CONCLUSIONS: We identified all tools that can be used to predict clinical outcomes for prostate cancer patients undergoing radical prostatectomy. While many were inaccurate or not well validated, we recommend the best available tools to help clinicians give patients accurate predictions. Use of these tools should help clinicians deliver accurate, evidence based counselling to patients undergoing radical prostatectomy.
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INTRODUCTION AND OBJECTIVES: Neuroendocrine carcinoma of the prostate (NEPC) is an uncommon histologic type, described only in few reports. The present study provides populationbased incidence rates and oncological outcomes for NEPC.
METHODS: The current analysis relied on a total of 309 individuals diagnosed with histologically-confirmed NEPC between 2004 and 2013 within the Surveillance, Epidemiology, and End Results (SEER) registries. Patients with unknown metastatic stage (Mx) were not considered. Age-adjusted incidence rates (AAI) was calculated after correction according to the 2000 United States standard population and plotted according to the year of diagnosis. Temporal trend for AAI was quantified using the annual percentage change (APC) with the least squares linear regression. Among NEPC individuals, those with small cell carcinoma (SCC) histological subtype were identified and stratification was performed according to SCC vs. non-SCC (NSCC) histological variant. Kaplan-Meier estimate plots described overall survival (OS) in the entire cohort, as well as after stratification according to metastatic status and histological subtype.
RESULTS: A total of 309 patients harboured NEPC. Of those, 60.2% (n¼186) harboured SCC. A total of 64.1% (n¼198) harboured metastatic disease. Annual AAI rates ranged from 0.23/1,000,000 person years in 2004 to 0.40/1,000,000 person years in 2013, with a statisticallysignificant increase over the study period (p¼0.02; Figure 1 ). Median survival in the overall population was 10 months, with a difference between SCC and NSCC that only bordered statistical significance (10 vs. 12 months; p¼0.05). Median survival was 13 versus 8 months for M0 vs. M1 disease (p<0.001). In SCC individuals, median survival was 12 versus 8 months for M0 vs. M1 disease (p<0.001). In NSCC, median survival was 15 vs. 9 months for M0 vs. M1 disease (p¼0.01) CONCLUSIONS: Despite a small but statistically-significant increase in NEPC incidence, it still represents a very rare entity. Most cases are represented by SCC. Survival is very poor, regardless of histological variant. While metastatic status at diagnosis confers worse survival rates, the absolute survival difference remains negligible.
